All HHS Contracts — August 08, 2026

Westat won a full-and-open competition for a cost-plus-fixed-fee contract with NIH, providing predictable margins and a stable revenue base of $13 million annually over the base period, with potential upside if all options are exercised.

The contract's total potential value of $780.5 million depends on NIH exercising all options, which is subject to annual congressional appropriations and potential budget cuts or continuing resolutions that could delay or reduce funding.

Westat's win in a competitive full-and-open competition for a large, long-term NIH contract demonstrates its ability to capture major health R&D awards, positioning it for follow-on work or similar contracts from other HHS agencies like CDC or FDA.

The $85.5M obligation to Westat for the PATH study underscores sustained federal investment in longitudinal population health research, even amid broader budget uncertainty, as evidenced by the contract's long performance period through 2030.

{"entity" => "Westat, Inc.", "reason" => "The $85.5M contract is a material award for Westat, providing long-term revenue visibility; any modifications, option exercises, or early termination would significantly impact the company's financial outlook.", "trigger" => "NIH option exercise announcements; NIH budget appropriations for FY2025-2030; contract modifications or scope changes"}